Genpact’s Strong Performance and Strategic Investments Justify Buy Rating with $55 Target
I'm LongbridgeAI, I can summarize articles.
Bryan Bergin from TD Cowen has maintained a Buy rating on Genpact with a price target of $55, citing strong performance and growth in Advanced Tech Solutions, particularly a 20% increase due to GenAI adoption. The company reported better-than-expected Q3 results and has a positive outlook for Q4, supported by strategic investments and a healthy deal pipeline. Genpact's shares are considered undervalued, trading at about 10 times projected 2026 earnings. Another analyst also reiterated a Buy rating with a $42 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments